Abstract:Liu, Yingwei ; Yi, Tao ; Meng, Shenglan ; Zhao, Xia ; Chen, Xiancheng ; Zhang, Yanna ; More attention has been paid to immunotherapy for ovarian cancer and the development of tumor vaccines. We developed a trichostatin A (TSA)-modified tumor vaccine with potent immunomodulating activities that can inhibit the growth of ovarian cancer in rats and stimulate immune cell response in vivo. TSA-treated Nutu-19 cells inactivated by X-ray radiation were used as a tumor vaccine in rat ovarian cancer models. Prophylactic and therapeutic experiments were performed with TSA-modified tumor vaccine in rats. Flow cytometry and ELISpot assays were conducted to assess immune response. Immune cell expression in the spleen and thymus were detected by immunohistochemical staining. GM-CSF, IL-7, IL-17, LIF, LIX, KC, MCP-1, MIP-2, M-CSF, IP-10/CXCL10, MIG/CXCL9, RANTES, IL-4, IFN-γ, and VEGF expressions were detected with Milliplex Map Magnetic Bead Panel immunoassay. TSA vaccination in therapeutic and prophylactic models could effectively stimulate innate immunity and boost the adaptive humoral and cell-mediated immune responses to inhibit the growth and tumorigenesis of ovarian cancer. This vaccine stimulated the thymus into reactivating status and enhanced infiltrating lymphocytes in tumor-bearing rats. The expression of key immunoregulatory factors were upregulated in the vaccine group. The intensities of infiltrating CD4+ and CD8+ T cells and NK cells were significantly increased in the vaccine group compared to the control group (P<0.05). This protection was mainly dependent on the IFN-γ pathway and, to a much lesser extent, by the IL-4 pathway. The tumor cells only irradiated by X-ray as the control group still showed a slight immune effect, indicating that irradiated cells may also cause certain immune antigen exposure, but the efficacy was not as significant as that of the TSA-modified tumor vaccine. Our study revealed the potential application of the TSA-modified tumor vaccine as a novel tumor vaccine against tumor refractoriness and growth. These findings offer a better understanding of the immunomodulatory effects of the vaccine against latent tumorigenesis and progression. This tumor vaccine therapy may increase antigen exposure, synergistically activate the immune system, and ultimately improve remission rates. A vaccine strategy designed to induce effective tumor immune response is being considered for cancer immunotherapy.

Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine

Eliciting Effective Tumor Immunity Against Ovarian Cancer by Cancer Stem Cell Vaccination

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Immunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity Against Ovarian Tumor-Initiating Cells in Mice

Extracellular Vesicles from Ipsc-Mscs Alleviate Chemotherapy-Induced Mouse Ovarian Damage Via the ILK-PI3K/AKT Pathway

Epithelial Ovarian Cancer: Feasibility of Image-Guided Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Gene Therapy

Abstract No. 576 Orthotopic Ovarian Cancer: Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase (HSV-TK) Gene Therapy

Vaccination With Embryonic Stem Cells Generates Effective Antitumor Immunity Against Ovarian Cancer

Whole Cancer Cell Vaccine Protects Ovarian Functions in Tumor-bearing Mice Through Downregulating CXCL10

Human embryonic stem cells--a potential vaccine for ovarian cancer.

Ovarian caremoma cell supernatants inhibit proliferation and IL-2R expression of CD8+ T cell

Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer

In vivo anti-tumor effect of tumor cell-derived exosomes combined with BCG

Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells

Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy

Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model

Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development

Suicidal Cancer Vaccine Enhances Anti-Tumor Immunotherapeutic Effect and Its Safety in the Treatment of Ovarian Cancer

Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy